• DOI:10.1002/pros.23728
Corpus ID: 53501532

Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients

@article{Sekino2019ProtocadherinBP,
  title={Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients},
  author={Yohei Sekino and N. Oue and S. Mukai and Y. Shigematsu and Keisuke Goto and N. Sakamoto and K. Sentani and T. Hayashi and J. Teishima and A. Matsubara and W. Yasui},
  journal={The Prostate},
  year={2019},
  volume={79},
  pages={234 - 242}
}

Yohei Sekino, N. Oue, +8 authors W. Yasui

Published 2019

Biology, Medicine

The Prostate

Background Prostate cancer (PCa) is a common malignancy worldwide and is the second leading cause of cancer death in men. The standard therapy for advanced PCa is androgen deprivation therapy (ADT). Although ADT, including bicalutamide treatment, is initially effective, resistance to bicalutamide frequently occurs and leads to the development of castration‐resistant PCa. Thus, clarifying the mechanisms of bicalutamide resistance is urgently needed. We designed this study to assess the… CONTINUE READING

View on Wiley

rss.onlinelibrary.wiley.com

Save to Library

Create Alert

Cite

Launch Research Feed